These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8353049

  • 1. Depletion of circulating cyst(e)ine by oral and intravenous mesna.
    Stofer-Vogel B, Cerny T, Küpfer A, Junker E, Lauterburg BH.
    Br J Cancer; 1993 Sep; 68(3):590-3. PubMed ID: 8353049
    [Abstract] [Full Text] [Related]

  • 2. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
    Lauterburg BH, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T.
    Cancer Chemother Pharmacol; 1994 Sep; 35(2):132-6. PubMed ID: 7987989
    [Abstract] [Full Text] [Related]

  • 3. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Pendyala L, Creaven PJ, Schwartz G, Meropol NJ, Bolanowska-Higdon W, Zdanowicz J, Murphy M, Perez R.
    Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
    [Abstract] [Full Text] [Related]

  • 4. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
    Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F.
    Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
    [Abstract] [Full Text] [Related]

  • 5. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK, Fahey RC, Dubowy RL, Newton GL, Bernstein ML.
    Cancer Chemother Pharmacol; 1999 May; 44(6):498-504. PubMed ID: 10550571
    [Abstract] [Full Text] [Related]

  • 6. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
    Jones MS, Murrell RD, Shaw IC.
    Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
    [Abstract] [Full Text] [Related]

  • 7. Determination of free and total cyst(e)ine in plasma of dogs and cats.
    Tôrres CL, Miller JW, Rogers QR.
    Vet Clin Pathol; 2004 May; 33(4):228-33. PubMed ID: 15570560
    [Abstract] [Full Text] [Related]

  • 8. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine.
    Aebi S, Assereto R, Lauterburg BH.
    Eur J Clin Invest; 1991 Feb; 21(1):103-10. PubMed ID: 1907548
    [Abstract] [Full Text] [Related]

  • 9. Plasma cysteine, cystine, and glutathione in cirrhosis.
    Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, Rudman D.
    Gastroenterology; 1984 Oct; 87(4):770-6. PubMed ID: 6468868
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA, Mant TG, Rogers HJ.
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [Abstract] [Full Text] [Related]

  • 11. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA, Cruz JM, Webb CD, Kucera GL, Perry JJ, Hurd DD.
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [Abstract] [Full Text] [Related]

  • 12. Maternal-fetal cyst(e)ine transfer.
    Malloy MH, Rassin DK, McGanity WJ.
    Biol Neonate; 1983 Apr; 44(1):1-9. PubMed ID: 6882840
    [Abstract] [Full Text] [Related]

  • 13. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 14. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity.
    Cavalletti E, Tofanetti O, Zunino F.
    Cancer Lett; 1986 Jul; 32(1):1-6. PubMed ID: 3091245
    [Abstract] [Full Text] [Related]

  • 15. Oral bioavailability of mesna tablets.
    Stofer-Vogel B, Cerny T, Borner M, Lauterburg BH.
    Cancer Chemother Pharmacol; 1993 Jul; 32(1):78-81. PubMed ID: 8462128
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Smith PF, Booker BM, Creaven P, Perez R, Pendyala L.
    J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
    [Abstract] [Full Text] [Related]

  • 17. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
    Souid AK, Fahey RC, Aktas MK, Sayin OA, Karjoo S, Newton GL, Sadowitz PD, Dubowy RL, Bernstein ML.
    Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
    [Abstract] [Full Text] [Related]

  • 18. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration.
    Burgunder JM, Varriale A, Lauterburg BH.
    Eur J Clin Pharmacol; 1989 Nov; 36(2):127-31. PubMed ID: 2721538
    [Abstract] [Full Text] [Related]

  • 19. New mixed disulfides of L-cysteine derivatives and of glutathione with diethyldithiocarbamic acid and 2-mercaptoethanesulfonic acid.
    Rajca A, Bertram B, Eisenbarth J, Wiessler M.
    Arzneimittelforschung; 1990 Mar; 40(3):282-6. PubMed ID: 2161235
    [Abstract] [Full Text] [Related]

  • 20. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC, Weeks MS.
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.